Ozempic and Wegovy: Do They Work the Same for Weight Management?

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic and Wegovy contain identical active pharmaceutical ingredients—semaglutide—but serve different medical purposes and patient populations. While Ozempic received FDA approval for type 2 diabetes management, Wegovy gained clearance specifically for chronic weight management in people with obesity or weight-related conditions. This distinction shapes how they are prescribed, dosed, and covered by insurance.

How Ozempic and Wegovy Differ Despite the Same Active Ingredient

Both medications deliver semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that slows stomach emptying and signals fullness to the brain. The core mechanism is identical: Ozempic and Wegovy bind to the same receptors and trigger the same physiological responses. However, their approved indications diverge significantly. Ozempic is labeled for improving glycemic control in adults with type 2 diabetes, while Wegovy is indicated for chronic weight management in adults with obesity or overweight with weight-related medical conditions. This labeling difference affects insurance coverage, patient eligibility, and how physicians prescribe each product.

Dosing schedules also reflect their distinct approved uses. Ozempic's maximum dose for diabetes is 2.0 mg once weekly, while Wegovy's weight management protocol goes up to 2.4 mg weekly. Insurance companies often require diabetes diagnosis to cover Ozempic, whereas Wegovy coverage depends on BMI and documented weight-related comorbidities. Out-of-pocket costs differ substantially: brand-name Wegovy typically costs significantly more than Ozempic at the pharmacy level, though both remain expensive for uninsured patients.

Semaglutide Effectiveness for Weight Loss Across Clinical Trials

The STEP trials demonstrated Wegovy's weight loss potential in non-diabetic populations. Participants receiving 2.4 mg semaglutide weekly lost an average of 10–15% of baseline body weight over 68 weeks, compared to 2–3% in placebo groups. When semaglutide was discontinued, weight regain occurred in most patients, indicating that treatment continuation is necessary to maintain results. These trials included adults with BMI ≥30 or BMI ≥27 with weight-related conditions, reflecting real-world patient populations seeking weight management solutions.

Ozempic's weight loss effects emerged as a secondary benefit in diabetes trials, with participants losing 2–4 kg on average. This smaller weight reduction reflects both its lower approved dose ceiling and its primary indication for glucose control rather than weight management. However, many physicians prescribe Ozempic off-label for weight loss because it costs less than Wegovy and insurance sometimes covers it more readily for diabetic patients. PlexusDx Compounded Semaglutide Injection delivers the same active ingredient at doses up to 2.4 mg weekly, at $189/mo month-to-month, or from $149/mo on the 6-month plan, without insurance requirements or membership fees.

Cost, Access, and Why Compounded Semaglutide Is Changing the Market

Brand-name Wegovy costs $1,350 to $1,500 monthly for uninsured patients, while Ozempic ranges from $900 to $1,200 per month depending on dose and pharmacy. Insurance coverage varies: some plans cover Wegovy with prior authorization, others only cover Ozempic for diabetes, and many deny both. This creates a coverage gap for patients with obesity who lack diabetes diagnosis and cannot afford brand-name prices. Compounding pharmacies offer a clinically equivalent alternative: licensed 503A compounding facilities can prepare semaglutide injections at lower costs because they operate outside the brand-name pricing structure.

PlexusDx partners exclusively with licensed 503A compounding pharmacies to deliver semaglutide at $189 per month starting dose, with pricing that remains flat regardless of dose escalation—a model designed to remove financial barriers. No insurance is required, no membership fee applies, and HSA/FSA accounts can be used. PlexusDx serves all 50 states and manages dose adjustments through digital consultation, allowing patients to access the same active ingredient available in Ozempic and Wegovy at a fraction of the cost. The clinical profile remains consistent because the underlying chemistry and receptor binding are identical.

How Your Genetics Relate to GLP-1 Pathways

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Understanding your genetic predisposition to GLP-1 response allows personalized dose titration and expectation-setting before treatment begins. Patients with favorable variants may reach target weight loss at lower doses, potentially saving money over time. Those with less responsive pathways benefit from knowing that dose escalation or combination therapies may be necessary from the outset. The Precision Peptide Genetic Test is $298, providing actionable data that complements traditional clinical assessments and helps optimize long-term outcomes.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic the same as Wegovy?

Ozempic and Wegovy contain identical semaglutide molecules and work through the same GLP-1 receptor mechanism. The difference lies in labeling, approved indication, and typical dosing: Ozempic targets type 2 diabetes with a maximum dose of 2.0 mg weekly, while Wegovy targets weight management at up to 2.4 mg weekly. Insurance coverage and out-of-pocket costs differ significantly between them.

How much weight can you lose with semaglutide?

Clinical trials show semaglutide at 2.4 mg weekly produces an average weight loss of 10–15% of baseline body weight over one year in people without diabetes. Results vary based on individual genetics, lifestyle, and dose tolerance. Genetic variants in GIPR, and FTO genes influence individual response rates significantly.

Why is PlexusDx Compounded Semaglutide cheaper than Wegovy?

PlexusDx uses licensed 503A compounding pharmacies that prepare semaglutide at lower cost than brand-name manufacturers. No insurance negotiation or marketing expense applies, allowing prices to start at $189 per month with no flat per-compound pricing increases. All 50 states are served without membership fees or insurance requirements.

What are the side effects of semaglutide, and are they the same in Ozempic and Wegovy?

Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. These occur because semaglutide slows stomach emptying regardless of brand. Serious but rare risks include pancreatitis and gallbladder issues. Side effect profiles are identical between products because the active ingredient is the same; individual tolerance depends on genetics and comorbidities.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx's genetic test identifies variants in GIPR and FTO, and MC4R genes that determine your body's responsiveness to GLP-1 therapy. This $298 test reveals whether you carry genetics favoring strong weight loss, modest reduction, or variable response, enabling personalized dose planning and realistic outcome expectations before beginning treatment.

Related Reading

• Ozempic For Losing Weight
• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Ozempic For Weight Loss 2

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.